Tagged with Association,

Switzerland With a population of only 350,000, Ticino has a remarkably well developed pharmaceutical cluster. FIT Chairman Giorgio Calderari explains that the cluster’s key strength lies in the diverse range of capabilities which its members are able to offer as contract services to one another, and of course other interested third…

Greece General Manager of the Hellenic Association of Pharmaceutical Companies (SFEE), Mihalis Himonas speaks about his role spearheading Greece’s main pharma association, the contribution of the pharma industry to GDP, market access challenges, and solutions for creating a sustainable healthcare environment. As the organization representing the united voice of the pharmaceutical…

Greece As the President of the Panhellenic Union of Pharmaceutical Industries (PEF), Theodore Tryfon shares the mission of the association, the main challenges plaguing the sector, as well as the measures in place to mitigate the difficult economic times and elevate the Greek brand in the upcoming years. As an introduction…

Switzerland The Swiss Biotech Association’s Nic Alexakis describes Switzerland’s thriving biotech scene and extensive support infrastructure, while also highlighting the gaps around early stage funding and the ability of different cantons to collaborate on economic development.  Switzerland of course has quite the reputation as a hub for biotech activity – how…

Switzerland For the eighth year in a row the World Economic Forum has ranked Switzerland first in both global competitiveness and in innovation; economiesuisse CEO Monika Rühl discusses the main issues which threaten this leading position, and the overall growth prospects for the Swiss economy. To begin, could you please introduce…

Luxembourg Founded just five years ago, the Luxembourg Pharmaceutical Association (APL) was created in response to the divergence of Luxembourg’s pharmaceutical regulatory environment with Belgium. At present, Secretary General Hendrik Kühne’s primary objective is to build a stronger dialogue and greater trust with the authorities, such that the industry can be…

Switzerland Walter P. Hölzle, president of vips, discusses the current priorities of the association, the importance of innovation, and the challenges of the current pricing system. While growth is close to zero for many pharmaceutical markets in Europe, Swiss pharma spending increased 4.5 percent in 2015. What would you identify as…

Philippines Higinio “JP” Porte, president of the Philippine Pharmaceutical Manufacturers Association, discusses how his extensive pharmaceutical background led him to his current role as well as the main objectives of the association moving forward. He also discusses his work to create comradery within the association, fostering an environment where members are…

Mexico Mayra Galindo Leal, general director of the Mexican Association of the Fight Against Cancer (AMLCC) provides an overview of the main milestones of this association that stands as the most important patient organization for cancer in Mexico, her expectations towards the pharmaceutical industry, and the main challenges she faces when…

Luxembourg Luxembourg has a young and ambitious life sciences community, which has identified four aspects of personalized medicine where the country has significant potential: digital health, neurodegenerative diseases, molecular diagnostics and immune-oncology. Thomas Dentzer, Head of the Life Sciences sector in Luxembourg, discusses the flexible and supportive atmosphere for companies and…

Mexico Alexis Serlin, country president of Novartis Mexico and president of CANIFARMA, the industry chamber that brings together multinational and local drug manufacturers, explains how the pharmaceutical industry in Mexico aims to be recognized as a strategic sector by both the Ministries of Health and Economy. He highlights Novartis Mexico’s leadership in…

Switzerland Thomas Cueni of Interpharma, the Association of Pharmaceutical Research Companies of Switzerland, on the trend of major international companies developing significant operations in Switzerland; how 70 percent of employees at the top pharma companies are foreigners; and why the pharmaceutical industry is the exception to the rule when it comes…